A full house, sharp discussions, and an afternoon in which science and industry visibly strengthened one another. The Dutch Medicines Winter Afternoon demonstrated that Groningen is not only a strong geographical spot, but also a substantive force within the Dutch life sciences landscape. The event, organized by FIGON (Federation for Innovative Drug Research Netherlands) in collaboration with LIFE Cooperative, brought professionals from across the Netherlands to the north.
Researchers, entrepreneurs, developers, and clinical experts gathered around one shared ambition: to bring innovative medicines to patients faster, smarter, and better.Klaas Poelstra, Chair of FIGON, looks back positively on the event: “It was great to see local businesses in the health sector and leading academic scientists engaging in conversation with one another. They have so much to gain from each other.“
What became particularly clear during the Dutch Medicines Winter Afternoon was how rapidly the field of drug development is evolving, and how essential collaboration has become. At a time when therapies are increasingly targeted, complex, and costly, the focus is shifting from only what we develop to how we do so: more intelligently, more sustainably, and better aligned with patient needs.
This broader context was already reflected in the opening remarks by Klaas Poelstra, who emphasized the importance of continued innovation for the Netherlands’ competitive position and patient care. On behalf of the LIFE Cooperative, Robert Hof highlighted that regional collaboration is a decisive factor: by bringing science, entrepreneurship, and clinical practice closer together, real acceleration can be achieved.
The first substantive contributions made it clear that innovation today is not only about new molecules, but also about new delivery methods. Rob Steendam demonstrated how long-acting microspheres can improve treatment adherence and reduce patient burden. Jaap Wieling showed how inhalation technology is evolving into a platform for both local and systemic therapies. Through her research on polyelectrolyte coacervates, Marleen Kamperman placed these innovations within a fundamental scientific framework.
After the break, the discussion shifted to clinical translation and advanced nanomedicines. Flávia Sousa illustrated how polymer-based nanomedicines contribute to targeted brain delivery. Ad Roffel underscored the importance of robust pharmacokinetic studies in an era where the demands for evidence continue to increase. Erik Frijlink reflected on innovation within both existing and new delivery systems, while Helder Santos outlined the potential of RNA delivery via nanotechnology for cardiac tissue repair.
During the closing networking reception, it became clear what participants had gained from the afternoon. As Robert Hof, Board Member of the LIFE Cooperative, put it:
“The FIGON Winter Afternoon was an excellent event with distinguished speakers and strong engagement. We look forward to the next edition and extend our sincere thanks to Klaas Poelstra and FIGON for hosting the event in the Northern Netherlands.”
The common thread throughout the afternoon was therefore unmistakable: the future of medicines does not lie within a single discipline, but in the connections between them. In a time of increasing healthcare pressure, rapid technological advancement, and international competition, such collaboration is not a luxury, it is a necessity.
The Dutch Medicines Winter Afternoon showed that this collaboration is firmly rooted in the Northern Netherlands and that Groningen is positioning itself emphatically as a breeding ground and accelerator for innovative drug development.
In het Noorden, en Groningen in het bijzonder, zitten tientallen bedrijven die zich bezighouden met innovaties op het gebied van life science en health. Veel pareltjes zitten erbij, zegt Ronald Hesse, directeur van samenwerkingsverband LIFE Cooperative. “Miljoenen patiënten wereldwijd hebben al kunnen profiteren van innovaties die hier in Groningen zijn ontwikkeld”, zegt hij.
Onderzoekers van het UMCG en spin‑off CC Diagnostics, lid van de LIFE Cooperative, hebben een nieuwe test ontwikkeld die het screenen op baarmoederhalskanker mogelijk efficiënter en gebruiksvriendelijker maakt.
Innovatie in geneesmiddelen staat centraal op donderdag 26 februari tijdens de Dutch Medicine Winter Afternoon, een inspirerende middag georganiseerd door FIGON (Federation for Innovative Drug Research Netherlands) in samenwerking met de LIFE Cooperative. “We zijn ontzettend trots op de sterke line-up tijdens dit event, waarbij toonaangevende experts vanuit wetenschap en industrie samenkomen en de grenzen van medicijnontwikkeling verkennen.
